 |
ADD DRUGS-WEB.COM AS FAVORITE - SITE MAP |
 |
HAEMOPHILIA TREATMENTS |
||
|
Various types of factors VIII and IX are
available to replace a patient's missing factors. These are
administered intravenously (directly into the patient's veins by
needle). These factor preparations may be obtained from a single
donor, by pooling the donations of as many as thousands of donors,
or by laboratory creation through highly advanced genetic techniques. The frequency of treatment with factors depends on the severity of the individual patient's disease. Patients with relatively mild disease will only require treatment in the event of injury, or to prepare for scheduled surgical or dental procedures. Patients with more severe disease will require regular treatment to avoid spontaneous bleeding. While appropriate treatment of hemophilia can both decrease suffering and be life-saving, complications associated with treatment can also be quite serious. About 20% of all patients with hemophilia A begin to produce chemicals within their bodies which rapidly destroy infused factor VIII. The presence of such a chemical may greatly hamper efforts to prevent or stop a major hemorrhage. Individuals who receive factor prepared from pooled donor blood are at risk for serious infections which may be passed through blood. Hepatitis, a severe and potentially fatal viral liver infection, may be contracted from pooled factor preparations. Recently, a good deal of concern has been raised about the possibility of hemophiliacs contracting a fatal slow virus infection of the brain (Creutzfeldt-Jakob disease) from blood products. Unfortunately, pooled factor preparations in the early 1980s were almost all contaminated with human immunodeficiency virus (HIV), the virus which causes AIDS. Currently, careful methods of donor testing, as well as methods of inactivating viruses present in donated blood, have greatly lowered this risk. But a large number of hemophiliacs were infected with HIV. In fact, some statistics show that HIV is still the leading cause of death among hemophiliacs. The most exciting new treatments currently being researched involve efforts to transfer new genes to hemophiliacs. These new genes would have the ability to produce the missing factors. As yet, these techniques are not being performed on humans, but there is great hope that eventually this type of gene therapy will be available. |
||
|
||
| HAEMOPHILIA RELATED ITEMS | ||
